Related Experiment Video
Updated: Jun 23, 2025
Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
Published on: April 26, 2018
DMT1 contributes to MF- 438 - mediated inhibition of glioma cells
Abstract:
Elevated SCD1 expression has been associated with enhanced cancer cell survival, proliferation, and resistance to therapy in many cancer types including gliomas. Hereby, we investigate the impact of MF-438 on SCD1-mediated lipid metabolism and its consequences on glioma growth and survival. Our data reveals an IDH mut -specific inhibitory effect of MF438 on gliomas. Also, we delineate a dual mechanism of action: while SCD1-mediated lipid metabolism is hindered by MF-438 treatment, MF-438 also exerts an SCD1-independent inhibition on DMT1 expression. Supporting data from the DMT1 blocker underscores its significance in MF-438's anti-glioma efficacy.
Insights
MF-438 inhibits glioma growth by targeting stearoyl-CoA desaturase 1 (SCD1)-mediated lipid metabolism. This drug shows a specific inhibitory effect in IDH-mutant gliomas, also impacting DMT1 expression.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Metabolism
Background:
- Elevated stearoyl-CoA desaturase 1 (SCD1) expression promotes cancer cell survival, proliferation, and therapeutic resistance in various cancers, including gliomas.
- SCD1 plays a critical role in lipid metabolism, influencing cell membrane composition and signaling pathways crucial for cancer progression.
Purpose of the Study:
- To investigate the impact of MF-438 on SCD1-mediated lipid metabolism in gliomas.
- To determine the consequences of MF-438 treatment on glioma growth and survival.
- To elucidate the specific mechanisms of action of MF-438 in glioma, including potential IDH mutation specificity.
Main Methods:
- In vitro and/or in vivo glioma models were utilized to assess the effects of MF-438.
- Lipid metabolism was analyzed to understand MF-438's impact on SCD1 activity.
- Gene expression analysis was performed to investigate MF-438's effect on DMT1 (divalent metal transporter 1).
Main Results:
- MF-438 demonstrated an IDHmut-specific inhibitory effect on gliomas.
- MF-438 treatment hindered SCD1-mediated lipid metabolism.
- MF-438 exhibited an SCD1-independent inhibition of DMT1 expression, which was supported by DMT1 blocker data.
Conclusions:
- MF-438 exhibits anti-glioma efficacy through a dual mechanism involving inhibition of SCD1-mediated lipid metabolism and SCD1-independent suppression of DMT1.
- The findings highlight MF-438 as a potential therapeutic agent for IDH-mutant gliomas.
- Targeting both SCD1 and DMT1 may represent a promising therapeutic strategy for glioma treatment.
